A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants	Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria	Recruiting	Phase 1	2026-09-09		NCT07005713

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
BeOne Medicines	76

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Chengdu Second Peoples Hospital	Chengdu	China	1
Dermatology Hospital of Southern Medical University	Guangzhou	China	5
Hangzhou First Peoples Hospital	Hangzhou	China	3
Peking University Third Hospital	Beijing	China	21
The Affiliated Hospital of Qingdao University Branch West Coast	Qingdao	China	4
The First Affiliated Hospital of Chongqing Medical University	Chongqing	China	9
The First Affiliated Hospital of Wenzhou Medical University	Wenzhou	China	87
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology	Wuhan	China	15
Xiangya Hospital of Central South University	Changsha	China	47